Sign up
Pharma Capital

BriaCell having discussions with pharma companies on combination therapies

BriaCell Therapeutics (OTCQB: BCTXF) CEO Bill Williams sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizuma. BriaCell is also developing Bria-OTS, a personalized immunotherapy to treat advanced breast cancer.


View full BCT profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.